Table 1.
Literature summary of in vivo tumor models where significant anti-tumor efficacy was reported when engineered PrAgs were administered in combination with various cytotoxins
| Engineered PrAg | Cytotoxin | In vivo Tumor Model |
|---|---|---|
| MMP-activated PrAg, PrAg-L1 | LF-HMAGGb | LL3, Lewis lung carcinoma syngraft (22) |
| B16-BL6, melanoma syngraft (22) | ||
| C32, melanoma xenograft (22) | ||
| HT144, melanoma xenograft (22) | ||
| A549, lung carcinoma xenograft (22) | ||
| Colo205, colon carcinoma xenograft (22) | ||
| BHT-101, anaplastic thyroid carcinoma orthotopic implant (23) | ||
|
| ||
| uPA-activated PrAg, PrAg-U2 | FP59c | LL3, Lewis lung carcinoma syngraft (19,20) |
| T241, fibrosarcoma syngraft (19,20) | ||
| B16-BL6, melanoma syngraft (19,20) | ||
| HT1299, non-squamous cell lung carcinoma xenograft (21) | ||
|
| ||
| LFa | B16-BL6, melanoma syngraft (25) | |
|
| ||
| dual MMP/uPA-activated PrAg, IC-PrAg (PrAg-L1-I210A + PrAg-U2-R200A) | FP59c | LL3, Lewis lung carcinoma syngraft (8) |
| T241, fibrosarcoma syngraft (8) | ||
| B16-BL6, melanoma syngraft (8) | ||
|
| ||
| LF-HMAGGb | HN12, head and neck squamous cell carcinoma xenograft (24) | |
| HN6, head and neck squamous cell carcinoma (24) | ||
| Hep2, head and neck squamous cell carcinoma (24) | ||
| Cal27, head and neck squamous cell carcinoma (24) | ||
a
LF is wild-type anthrax lethal factor, with the native N-terminal sequence AGG
b
LF-HMAGG is a version of LF having the non-native N-terminal sequence HMAGG
c
FP59 is a fusion protein containing the PrAg binding domain of LF fused to the catalytic domain of Pseudomonas aeruginosa exotoxin A